Further development of a successful protocol of graft versus leukemia without fatal graft-versus-host disease in AKR mice

We previously reported a successful model for treatment of BW 5147 leukemia in AKR mice by adoptive immunotherapy using allogeneic spleen cells from C57BL/6 mice. The leukemia cells were given 3 days before initiation of therapy. Graft-versus-host reaction was prevented by treatment with spleen cell...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 1977-10, Vol.37 (10), p.3494
Main Authors: Chester, S J, Esparza, A R, Flinton, L J, Simon, J D, Kelley, R J, Albala, M M
Format: Article
Language:English
Subjects:
Animals
Cyclophosphamide - pharmacology
Female
Graft vs Host Reaction
Histocompatibility
Immunization, Passive
Leukemia, Experimental - immunology
Leukemia, Experimental - pathology
Leukemia, Experimental - therapy
Male
Mice
Mice, Inbred AKR
Mice, Inbred C57BL
Mice, Inbred CBA
Neoplasm Transplantation
Spleen - cytology
Spleen - immunology
Spleen - transplantation
Time Factors
Transplantation, Homologous
Transplantation, Isogeneic
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We previously reported a successful model for treatment of BW 5147 leukemia in AKR mice by adoptive immunotherapy using allogeneic spleen cells from C57BL/6 mice. The leukemia cells were given 3 days before initiation of therapy. Graft-versus-host reaction was prevented by treatment with spleen cells from a second allogeneic strain (CBA), followed by cyclophosphamide and syngeneic spleen cells. We now show that it is not necessary to use syngeneic spleen cells in the final transplant since H-2-compatible, allogeneic CBA cells are as effective. In addition, it is possible to initiate successful therapy 5 days after leukemia implantation providing that the initial cyclophosphamide, given in two doses of 100 mg/kg each and spaced 7 days apart, is administered prior to establishment of graft-versus-host reaction. Higher single doses of drugs were followed by fatal graft-versus-host disease.
ISSN:0008-5472